This is a type of medicine used to treat a specific kind of skin cancer called melanoma. It works by blocking a protein that helps the cancer grow.
Every report comes from a Lived member, sent anonymously.
Have you tried Zelboraf (Vemurafenib) for Melanoma?
Vemurafenib, sold as Zelboraf, is a targeted cancer pill used for melanoma that cannot be removed with surgery or has spread to other parts of the body, when the tumor carries a specific change in the BRAF gene called V600E. It is also approved for Erdheim-Chester disease, a rare condition in which a type of white blood cell builds up in bones and organs, when that disease carries a BRAF V600 mutation. Because it only works against BRAF-mutated disease, a sample of the tumor must be tested before treatment. In melanoma without the BRAF mutation, vemurafenib does not help and can actually encourage cell growth. For melanoma, it is often given together with cobimetinib (Cotellic), a related targeted drug, and sometimes also with the immunotherapy atezolizumab (Tecentriq). For many people with advanced melanoma, current guidelines favor immunotherapy as the first treatment, so a BRAF-targeted combination may be chosen instead or used later.
BRAF is a protein that passes along signals telling cells when to grow and divide. In some melanomas, a mutation leaves BRAF stuck in the on position, so cancer cells keep receiving a growth signal even when nothing outside the cell is asking for it. Vemurafenib blocks the mutated BRAF protein, cutting off that signal and causing many BRAF-mutated tumors to shrink. Cancer cells often find ways around the block over time, which is why the benefit can fade. Adding cobimetinib, which blocks MEK, the next step in the same signaling chain, makes it harder for the tumor to work around the blockade and helps the response last longer.
Vemurafenib comes as 240 mg tablets. The usual dose is four tablets taken twice a day, about 12 hours apart, with or without food. Swallow the tablets whole; do not crush or chew them. When it is part of the three-drug combination with atezolizumab, the dose is lower, and cobimetinib follows its own schedule of three weeks on and one week off. If a dose is missed, it can be taken up to 4 hours before the next scheduled dose; otherwise skip it. If you vomit after a dose, do not take an extra one. Treatment usually continues as long as it is working and side effects are manageable. Doses are often lowered or paused to handle side effects, so follow the care team's current instructions rather than the original prescription.
The most common effects are joint pain, rash, itching, hair thinning, tiredness, nausea and small skin growths. Sun sensitivity is common and can be marked, so even brief sun exposure may cause a burn. Wear protective clothing and use broad-spectrum sunscreen and lip balm of at least SPF 30 outdoors. About a quarter of people develop new skin cancers, mostly squamous cell carcinomas, often within the first two months. These are usually caught early by a dermatologist and cut out, and vemurafenib can generally continue. Skin checks are recommended before starting, every 2 months during treatment and for up to 6 months after stopping. Report any new growth, sore that does not heal or change in a mole promptly. Contact the care team right away about eye pain, redness, blurred vision or light sensitivity, which can signal inflammation inside the eye (uveitis), and about a severe rash, especially one with blistering or peeling skin. Rarely, a serious allergic reaction occurs; trouble breathing, swelling of the face or throat, or a widespread rash with feeling faint means stopping the medicine and getting emergency care.
Vemurafenib can affect the heart's electrical rhythm by lengthening the QT interval, a measure on an electrocardiogram (ECG) of how long the heart takes to recharge between beats. A longer interval raises the risk of a dangerous irregular rhythm. ECGs and blood levels of potassium, magnesium and calcium are checked before and during treatment, and other medicines that lengthen the QT interval need review. Liver blood tests are done before starting and monthly, and kidney function is checked periodically. Some medicines change vemurafenib levels. Rifampin (an antibiotic) and the seizure medicines phenytoin and carbamazepine can lower them, while some other medicines can raise them, so a pharmacist should review any new prescription. Vemurafenib can also raise levels of tizanidine (a muscle relaxant) and digoxin (a heart medicine). Tell the care team about radiation treatment, past or planned, because vemurafenib can intensify radiation damage to skin and internal organs, occasionally severely. Vemurafenib can harm a developing baby. People who could become pregnant should use effective contraception during treatment and for 2 weeks after the last dose, and should not breastfeed during that time. When it is combined with cobimetinib, that drug adds its own monitoring, including heart scans and eye exams.
In melanoma, vemurafenib often works quickly: in clinical trials, tumors that responded usually did so within the first one to two months, and about half of people saw meaningful shrinkage. Compared with older chemotherapy, it helped people live longer. However, the response often lasts months rather than years when vemurafenib is used alone, which is one reason it is now usually paired with cobimetinib. In Erdheim-Chester disease, improvement tends to be slower, often taking many months. Treatment involves regular visits for scans, blood tests, ECGs and skin checks, especially early on. Many people need a dose reduction at some point, and this does not necessarily mean the drug is working less well. If the disease starts growing again, the team will discuss switching to another treatment such as immunotherapy.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Zelboraf (Vemurafenib), what you've noticed, or ask the community a question.